Only 10 percent of early prostate tumors become life-threatening, he explained, but there's no way to distinguish them from the 90 percent that aren't. Without treatment, he thought he would have a 10 percent chance it might be fatal. But treatment side effects include a high risk of lifelong incontinence and erectile dysfunction, and he believed there would be a 90 percent chance that treatment would be unnecessary. He confessed he wouldn't know what to do.
I recalled his dilemma while reading Richard J. Ablin's just published The Great Prostate Hoax: How Big Medicine Hijacked the PSA Test and Caused a Public Health Disaster. Ablin is the scientist who, in 1970, discovered PSA, or prostate-specific antigen — a protein whose level in the blood usually spikes upward in men with prostate cancer. Yet today Ablin accuses PSA of being a lousy test for prostate cancer because:
- PSA does not diagnose cancer. A man with a low PSA can have cancer, yet most men with high PSAs do not.
- A high PSA can be caused by many other things besides cancer — among them infections, sex (partner or solo), sitting for long periods and normal age-related prostate enlargement.
- Prostate cancer is virtually inevitable with age; autopsy men over 85, and almost 100 percent will show it. Hence this medical adage: Some men die from prostate cancer, but all old men die with it.
- High PSAs lead to more than 1 million annual prostate biopsies, which in turn cause 100,000 men a year to seek treatment for prostate cancer; most of the 100,000 have tumors that will never endanger their lives.
Ablin, who refuses to have his PSA tested, goes so far as to call PSA screenings "a hugely expensive public health disaster."
PSA testing has hardly been a financial disaster for urologists, however; they practically mint money from costly biopsies and surgical treatment. Not surprisingly, many urologists champion routine PSA screening. But other doctors, meanwhile, have cooled on the test:
- In 731 men with stage 1 prostate cancer, University of Minnesota researchers either removed the gland (radical prostatectomy) or did nothing (watchful waiting). After 12 years, the treated men's death rate from prostate cancer was less than 3 percent below those not treated.
- Scientists at Washington University in St. Louis did yearly screenings of the PSA levels in 38,000 men. At the same time, 38,000 control subjects were tested less frequently — if at all. "After seven years, the death rate from prostate cancer did not differ significantly between the two groups."
- Dutch researchers tested PSA in some 91,000 men every four years; a separate group of the same size was never tested. After nine years, the prostate cancer death rate was slightly lower in the tested group, but the testing had also resulted in a great deal of overdiagnosis and overtreatment.